Khona Scientific Inc. (KSI) is a synthetic biology company using a patented biosynthesis platform (BiDS™) to produce rare cannabinoids. These cannabinoids are made in very small quantities within plants, and thus cannot be produced cost-effectively using agricultural methods. KSI is positioning itself as an industrial-scale B2B supplier of cGMP-grade cannabinoids for companies making consumer products across multiple verticals including: - Health & Beauty/Cosmetics - Veterinary - Food & Beverage - Nutraceuticals Competing technologies address the problem of cannabinoid biosynthesis using a "step-wise" approach. In contrast, the BiDS™ platform organizes the 20+ biological steps necessary for cannabinoid production into an "assembly line". This "systems-level" approach to biosynthesis mimics nature, allowing targeted and efficient production of key cannabinoids. BiDS™ cannabinoid production - key takeaways: Plant-free (uses yeast and sugar) 90% conversion efficiency @ 24 hours Industrially viable yields (even before optimization) 100% THC-free Production in a controlled environment No contaminants (mold, pesticides, heavy metals) Offers a transparent & traceable supply chain Initial production: CBG, CBGa, CBC, CBCa, CBD, CBDa Future production: CBGV, CBGVa, CBCV, CBCVa, CBDV, CBDVa, THCV, THCVa, CBN, CBNa, CBV, CBT, CBTV, and CBLV Commercial production begins Q3 2023.
